Novo Nordisk is working on a new obesity drug that could ... months as investors fret that demand for weight-loss ...
Ozempic mimics the GLP-1 hormone the body naturally produces after eating, suppressing appetite and stimulating weight ...
SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of ...